WO1998017285A1 - Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics - Google Patents

Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics Download PDF

Info

Publication number
WO1998017285A1
WO1998017285A1 PCT/IB1997/001288 IB9701288W WO9817285A1 WO 1998017285 A1 WO1998017285 A1 WO 1998017285A1 IB 9701288 W IB9701288 W IB 9701288W WO 9817285 A1 WO9817285 A1 WO 9817285A1
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
solution
medicament
topical administration
bupivacaine
Prior art date
Application number
PCT/IB1997/001288
Other languages
French (fr)
Inventor
Aurelio Romeo
Bruno Silvestrini
Gunter Kirschner
Original Assignee
Fidia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia S.P.A. filed Critical Fidia S.P.A.
Priority to US09/284,668 priority Critical patent/US6224857B1/en
Priority to CA002268967A priority patent/CA2268967C/en
Priority to PL97332873A priority patent/PL190385B1/en
Priority to DE69732049T priority patent/DE69732049T2/en
Priority to AT97943093T priority patent/ATE285241T1/en
Priority to JP51916298A priority patent/JP4334620B2/en
Priority to BR9713486-4A priority patent/BR9713486A/en
Priority to AU44700/97A priority patent/AU712927B2/en
Priority to EP97943093A priority patent/EP0956026B1/en
Publication of WO1998017285A1 publication Critical patent/WO1998017285A1/en
Priority to HK00102836A priority patent/HK1023518A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to the use of new pharmaceutical preparations in the field of local anaesthetics and, more precisely, preparations consisting of a stoichiometrically neutral salt of a hyaluronic acid with a basic anaesthetic with local action containing aliphatic and/or aromatic amino groups with an aliquot of the carboxy groups of hyaluronic acid possibly salified with an alkaline or alkaline earth metal.
  • the invention also concerns some new compositions of the aforesaid type which, thanks to their specific pharmaceutical properties as described hereafter, are suitable for use as infiltrations and injections as well as for surface use
  • European patent No 0197718 Bl granted on December 15, 1993 describes the advantageous use of hyaluronic acid and molecular fractions thereof as vehicles for medicinal substances for topical use and demonstrates that associations of hyaluronic acid with known drugs in various fields of medicine give better effects than the same drugs administered on their own. That patent emphasises above all a greater degree of bioavailability than that obtained with the pharmaceutical formulations used in the past, and this advantage is illustrated especially in the ophthalmic field, where marked compatibility with the corneal epithelium was observed, with subsequent excellent tolerability with no sensitization effects, with the formation of homogeneous and stable films which are perfectly transparent, have excellent adhesive properties and guarantee prolonged bioavailability of the drug.
  • the above patent discusses the importance of said perfected bioavailability in the veterinary field with regard to the administration of chemotherapeutics.
  • the patent also lists miotic, anti- inflammatory, wound healing and antimicrobial effects for ophthalmic use in the fields of both veterinary and human medicine.
  • hyaluronic acid indicates a purified hyaluronic acid such as those already on the market or described in the literature or in patents such as those obtained by extraction from animal or fermentation sources, or of biotechnological origin, or molecular fractions of hyaluronic acids, likewise purified, such as those described in European patent No. 0138572 (describing commercial products known as Hyalastine and Hyalectin) or hyaluronic acids with higher molecular weights such as the fraction known as Hyaloftil, described in EP 0535200 Al, or other products available on the market.
  • hyaluronic acid Besides the hyaluronic acid described above, its partial esters obtained according to the procedure described in EP 0216453 Bl can also be used.
  • the local anaesthetics for use in the preparation of salts with hyaluronic acid according to the present invention are essentially those reported in the literature and/or found on the market or used for clinical purposes, and which contain aliphatic and/or aromatic amino groups (with between 12 and 30 carbon atoms) which can be salified with an acid. While the salts of hyaluronic acid with lidocaine, dibucaine and benzocaine are known, as they are described in the aforesaid European patent No.
  • the salts of hyaluronic acid with the following aminic-type local anaesthetics to be used according to the invention are new and constitute a particular object of the invention: tetracaine, amylocaine, bucricaine, bupivacaine, butacaine sulfate, butanilicaine, butoxycaine, car- ticaine, chloroprocaine, clibucaine, chlormecaine, cyclomethycaine, dimethisoquin hydrochloride, diperodon, diclocaine, ethyl p-piperidine acetylamine benzoate, ethidocaine, hexylcaine, phenacaine, fomocaine, hydroxyprocaine, hydroxytetracaine, ketocaine, oxethazaine, oxybuprocaine, paretoxy- caine, piperocaine, piridocaine, pyrrocaine, pramoxine, pri
  • the salts of hyaluronic acid with a strong anaesthetic effect according to the present invention are above all stoichiometrically neutral salts with the abovesaid aminic bases, that is, the total salts of the polysaccharide with aminic bases.
  • the degree of salification may vary within an ample range, for example between 10% and 90%, preferably between 20% and 80%, and especially between 50% and 75%, with the remaining carboxy groups of the polysaccharide are salified with one of the abovesaid ions of an alkaline or alkaline earth metal.
  • a preferred object of the invention is represented by the total and partial salts, as described above, of benzydamine with a hyaluronic acid. It has been observed that salts of this kind not only present a far more pronounced and longer-lasting anaesthetic effect than benzydamine or the hydrochloride thereof but also enhance the anti-inflammatory effect and, surprisingly reduce the irritating action, thus widening the gap between active and irritant concentrations or doses.
  • benzydamine presents some disadvantages, such as the brevity of its topical action, as the drug quickly passes from the application site into the system, and the onset of an irritant action, which occurs at doses not far removed from those required for the desired effects. It has further been found according to the invention that the activity of the hyaluronic acid salts with anaesthetics can vary depending upon the molecular weight of the hyaluronic acid. For one of the preferred anaesthetics, benzydamine, it was found that the product has the most improved characteristics when salified with a low molecular weight fraction of hyaluronic acid.
  • bupivacaine For another preferred anaesthetic, bupivacaine, it was found that the product has the most improved characteristics when salified with a high molecular weight fraction of hyaluronic acid. It has also been found that of the alkaline and alkaline earth metals, sodium salts are the preferred monovalent salts, and calcium salts are the preferred bivalent salts.
  • the new benzydamine salts of the present invention besides their advantageous application in ophthalmology, like the other anaesthetic bases mentioned previously, have proved to be new drugs with a very wide field of application, for example in inflammatory processes in the mouth or airways such as stomatitis of various origin, tonsillitis or tracheitis, in mucositis caused by radio- or chemotherapy, by surgical or diagnostic intubation, such as bronchoscopy, in dental and gingival disorders in general, including teething trouble in babies, in rhinitis, in inflammatory processes affecting the auditory canal, in conjunctivitis of various origin, in proctological conditions, in traumatic and degenerative-inflammatory processes in the joints, in vulvovaginitis and urethritis of various kinds, including those caused by radio- and chemotherapy, surgical operations, diagnostic manoeuvres, childbirth and, in general, any inflammatory disorder of any kind.
  • Corneal anaesthesia was assessed by the method of Camougis and Tankman (Camougis et al. (1971), "Methods in Pharmacology", Vol. 1, A. Schwartz Ed., Appleton-Century-Crofts, New York, p. 1) by measuring the blinking reflex in rabbit. Fifty ml of solution was instilled in the conjunctival sac. The blinking reflex, tested with a bristle, was measured before instillation and then every 5-10 minutes until one hour after treatment. At each test time the degree of anaesthesia was expressed by means of a score of up to 10 given by the number of stimulations before the eye-blink reflex was obtained. The overall anaesthetic effect for each compound was then quantified by the area under curve (AUC) of the degree of anaesthesia over time.
  • AUC area under curve
  • the hyaluronate salts of lidocaine, bupivacaine and benzydamine present greater local activity than their respective hydrochloride salts.
  • the effect of increasing the action of the anaesthetics varies according to the alkaline or alkaline/earth ion; the presence of calcium, unlike sodium, selectively favours lidocaine rather than bupivacaine or benzydamine.
  • Table 1 Anaesthetic effect in rabbit eye by hyaluronate of lidocaine, bupivacaine, benzydamine (FID 60.20XX) and their respective hydrochloride salts.
  • hyaluronate salts For the hyaluronate salts, the % of active principle and that of alkaline or alkaline earth ion are shown; ⁇ the doses refer in all cases to the active principle as a hydrochloride salt; $ AUC measurements of the anaesthetic effect are calculated by taking the reference active principle value as 100. This ion selectivity has proved to also depend upon the molecular weight of the hyaluronic acid used.
  • the ion selectivity only exists in low-molecular-weight hyaluronic acid, specifically molecular weight range of 50-350 kDa (derivatives FID 6020XX), and not in high-molecular-weight hyaluronic acid, molecular weight range of 500-730 Kda and 750-1200 (derivatives FID 61.20XX and FID 62.20XX, respectively).
  • Table 2 Anaesthetic effect in rabbit eye by hyaluronate salts of bupivacaine, according to the molecular weight of the hyaluronic acid of the alkaline or alkaline earth counterion.
  • the degree of activity depends on the molecular weight of the hyaluronic acid used.
  • Table 3 Anaesthetic effect on rabbit eye by hyaluronate salts of bupivacaine according to the molecular weight of the hyaluronic acid.
  • Table 4 Anaesthetic effect on rabbit eye by hyaluronate salts of lidocaine and its alkaline salts.
  • the degree of salification influences the biological activity of the derivatives, as can be seen in Table 5, where partial salts with bupivacaine and sodium of hyaluronic acid having a molecular weight range between 500 and 730 Kda are reported in comparison to the hydrochloride and the total salt; and in Table 6, where partial salts with benzydamine and sodium of hyaluronic acid having a molecular weight range between 50 and 350 Kda are reported in comparison to the hydrochloride.
  • Table 5 Anaesthetic effect on rabbit eye by hyaluronate salts of bupivacaine according to the degree of salification.
  • Table 6 Anaesthetic effect on rabbit eye by hyaluronate salts of benzydamine according to the degree of salification.
  • 0.1 ml of each of the test solutions was injection into the hind paw of rat.
  • the paw volume was measured with a plethismometer before injection and then 30-60- 120-240-480 minutes after.
  • the oedema and consequent irritant effect were measured on the basis of the increase in the volume of the paw.
  • the irritant effect is expressed by the sum of the increase in volume at the various measuring times.
  • the hyaluronate salt proved to be less irritating than the hydrochloride salt, as indicated by its lesser oedema-forming effect (Table 7).
  • Table 7 Irritant effect of benzydamine Hcl and FID 60.2108 in rat paw.
  • the hyaluronic acid sodium salt (molecular weight 50 - 350 Kda) is solubilized in water to a concentration of 16 mg/ml.
  • a column is filled with acid resin Bio-Rad AG50W-X8, pretreated with Hcl IN, using a glass column fitted with a jacket inside which there is a flow of fluid at 4°C; 5 ml of resin in acid form are loaded in the column and washed with water to a neutral Ph.
  • the solution of hyaluronic acid sodium salt is passed through the resin, and the resulting solution is collected in a container with a thermostat set at 4°C.
  • the flow in the column is regulated by a peristaltic pump fitted to the outlet of the column.
  • the resin is washed with water to minimize any loss of product, and the products of these washes are added to the hyaluronic acid solution, thus obtaining a final solution with a concentration of 11.8 mg/ml, expressed as hyaluronic acid.
  • the hyaluronic acid sodium salt (molecular weight 500 - 730 Kda) is solubilized in water to a concentration of 5.0 mg/ml.
  • a column is filled with acid resin Bio-Rad AG50W-X8, pretreated with HCl IN, using a glass column fitted with a jacket, inside which fluid flows at a temperature of 4°C; 5 ml of resin in acid form are loaded in the column and washed with water until a neutral pH is reached. At this point the hyaluronic acid sodium salt solution is passed through the resin, collecting the resulting solution in a container set at temperature of 4°C.
  • the fluid in the column is regulated by a peristaltic pump fitted onto the outlet of the column.
  • Hyaluronic acid sodium salt (molecular weight 750 - 1200 kDa) is solubilized in water to a concentration of 3.0 mg/ml.
  • a column is filled with acid resin.
  • the hyaluronic acid sodium salt is passed through the resin, collecting the resulting solution in a container with a thermostat set at 4°C.
  • the flow through the column is regulated by a peristaltic pump fitted onto the outlet of the column.
  • the benzydamine to use as starting product can be prepared as of follows: 3.0 g of benzydamine hydrochloride are solubilized in water at a concentration of 50 mg/ml. An equimolar quantity of NaOH IN is added, plus 5% excess, so as to give the aqueous solution a pH of between 10 and 11.
  • the benzydamine to be used as starting product can be prepared as described in Example 4.
  • Example 6 80 ml of an aqueous solution of hyaluronic acid, prepared as described in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop into the hyaluronic acid solution. A white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution.
  • the benzydamine used as starting product can be prepared as described in Example 4.
  • Example 7 80 ml of an aqueous solution of hyaluronic acid, prepared as described in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution.
  • the benzydamine used as starting product can be prepared as described in Example 4.
  • the benzydamine used as starting product can be prepared as described in Example 4.
  • the benzydamine used as starting product can be prepared as described in Example 4.
  • Example 10 400 ml of an aqueous solution of hyaluronic acid, prepared as in Example 3, at a concentration of 2.36 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution. A white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 10 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution. Some hours later, when there is no more suspended precipitate in the solution, 1.25 ml of NaOH is added and the mixture is shaken for another 30 minutes.
  • the benzydamine used as starting product can be prepared as described in Example 4.
  • the benzydamine used as starting product can be prepared as described in Example 4.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried.
  • the neutral salt partially salified (50%) with bupivacaine and partially salified (50%) with calcium is thus obtained.
  • the bupivacaine used as starting product can be prepared as described in Example 12
  • the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried.
  • the stoichiometrically neutral salt of hyaluronic acid with lidocaine is thus obtained.
  • the lidocaine used as starting product can be prepared as follows; 3.0 g of lidocaine hydrochloride is solubilized in water to a concentration of 25 mg/ml. An equimolar quantity of NaOH is slowly added, plus an excess of 5%, so as to give the aqueous solution a pH of between 10 and 11. In these conditions, lidocaine base is released and this separates from the water in the form of a precipitate.
  • the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried.
  • the neutral salt partially salified (75%) with lidocaine and partially salified (50%) with sodium is thus obtained.
  • the lidocaine used as starting product can be prepared as described in Example 24.
  • the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried.
  • the neutral salt partially salified (50%) with lidocaine and partially salified (50%) with sodium is thus obtained.
  • the lidocaine used as starting product can be prepared as described in Example 24.
  • the lidocaine used as starting product can be prepared as described in Example 24.
  • the lidocaine used as starting product can be prepared as described in Example 24.
  • the lidocaine used as starting product can be prepared as described in Example 24.
  • the lidocaine used as staring product can be prepared as described in Example 24.
  • Example 31
  • the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried.
  • the neutral salt partial salified (50%) with lidocaine and partially salified (50%) with potassium is thus obtained.
  • the lidocaine used as starting product can be prepared as described in Example 24.
  • the benzydamine to be used as starting product can be prepared as described in Example 4.
  • Example 33 80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.19 g of benzydamine base are diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert- butanol which are then added to the hyaluronic acid solution.
  • the benzydamine to be used as starting product can be prepared as described in Example 4.
  • the benzydamine to be used as starting product can be prepared as described in Example 4.
  • the bupivacaine used as starting product can be prepared as described in Example 12.
  • Preparation 3 Preparation of a proctological cream containing Benzydamine hyaluronate (75%) 100 ml of cream contain: - Benzydamine hyaluronate 1190 mg (equal to 448 mg of benzydamine base) Excipients

Abstract

Pharmaceutical preparations are described, comprised of salts of hyaluronic acid with a basic anaesthetic containing aliphatics and/or amino groups, particularly salts with benzydamine or bupivacaine.

Description

PHARMACEUTICAL PREPARATIONS COMPRISED OF SALTS OF HYALURONIC ACID WITH LOCAL ANAESTHETICS
Field of the invention
The present invention relates to the use of new pharmaceutical preparations in the field of local anaesthetics and, more precisely, preparations consisting of a stoichiometrically neutral salt of a hyaluronic acid with a basic anaesthetic with local action containing aliphatic and/or aromatic amino groups with an aliquot of the carboxy groups of hyaluronic acid possibly salified with an alkaline or alkaline earth metal.
The invention also concerns some new compositions of the aforesaid type which, thanks to their specific pharmaceutical properties as described hereafter, are suitable for use as infiltrations and injections as well as for surface use
Field of the invention
European patent No 0197718 Bl granted on December 15, 1993 describes the advantageous use of hyaluronic acid and molecular fractions thereof as vehicles for medicinal substances for topical use and demonstrates that associations of hyaluronic acid with known drugs in various fields of medicine give better effects than the same drugs administered on their own. That patent emphasises above all a greater degree of bioavailability than that obtained with the pharmaceutical formulations used in the past, and this advantage is illustrated especially in the ophthalmic field, where marked compatibility with the corneal epithelium was observed, with subsequent excellent tolerability with no sensitization effects, with the formation of homogeneous and stable films which are perfectly transparent, have excellent adhesive properties and guarantee prolonged bioavailability of the drug.
The above patent discusses the importance of said perfected bioavailability in the veterinary field with regard to the administration of chemotherapeutics. The patent also lists miotic, anti- inflammatory, wound healing and antimicrobial effects for ophthalmic use in the fields of both veterinary and human medicine.
Detailed description of the invention
It has now been discovered that the use of local anaesthetics, and more precisely basic organic anaesthetics containing amino groups, if used in the form of their stoichiometrically neutral salts with hyaluronic acid, or stoichiometrically neutral salts of hyaluronic acid with such anaesthetics, resulting from partial salification of the hyaluronic acid with said aminic substances and from the salification of the remaining carboxy groups of the acid with inorganic bases deriving from alkaline or alkaline earth metals, not only offers the advantages of enhanced bioavailability and excellent tolerability, but also induce an exceptional increase in the anaesthetic effect. This result is of great importance in the ophthalinological field but can be used in other fields as well. It constitutes a specific technical effect over and above the benefits reported in the aforesaid previous patent.
In the context of the present invention, the term "hyaluronic acid" indicates a purified hyaluronic acid such as those already on the market or described in the literature or in patents such as those obtained by extraction from animal or fermentation sources, or of biotechnological origin, or molecular fractions of hyaluronic acids, likewise purified, such as those described in European patent No. 0138572 (describing commercial products known as Hyalastine and Hyalectin) or hyaluronic acids with higher molecular weights such as the fraction known as Hyaloftil, described in EP 0535200 Al, or other products available on the market. Besides the hyaluronic acid described above, its partial esters obtained according to the procedure described in EP 0216453 Bl can also be used. The local anaesthetics for use in the preparation of salts with hyaluronic acid according to the present invention are essentially those reported in the literature and/or found on the market or used for clinical purposes, and which contain aliphatic and/or aromatic amino groups (with between 12 and 30 carbon atoms) which can be salified with an acid. While the salts of hyaluronic acid with lidocaine, dibucaine and benzocaine are known, as they are described in the aforesaid European patent No. 0197718 Bl, the salts of hyaluronic acid with the following aminic-type local anaesthetics to be used according to the invention are new and constitute a particular object of the invention: tetracaine, amylocaine, bucricaine, bupivacaine, butacaine sulfate, butanilicaine, butoxycaine, car- ticaine, chloroprocaine, clibucaine, chlormecaine, cyclomethycaine, dimethisoquin hydrochloride, diperodon, diclocaine, ethyl p-piperidine acetylamine benzoate, ethidocaine, hexylcaine, phenacaine, fomocaine, hydroxyprocaine, hydroxytetracaine, ketocaine, oxethazaine, oxybuprocaine, paretoxy- caine, piperocaine, piridocaine, pyrrocaine, pramoxine, prilocaine, procaine, propanocaine, propipocaine, propoxycaine, proxymetacaine, ropivacaine, tolycaine, trimecaine, vadocaine and, especially, benzydamine, a drug characterized by anti-inflammatory and local anaesthetic properties. The salts of hyaluronic acid with a strong anaesthetic effect according to the present invention are above all stoichiometrically neutral salts with the abovesaid aminic bases, that is, the total salts of the polysaccharide with aminic bases. In the partial salts of the polysaccharide with said aminic bases, the degree of salification may vary within an ample range, for example between 10% and 90%, preferably between 20% and 80%, and especially between 50% and 75%, with the remaining carboxy groups of the polysaccharide are salified with one of the abovesaid ions of an alkaline or alkaline earth metal. A preferred object of the invention is represented by the total and partial salts, as described above, of benzydamine with a hyaluronic acid. It has been observed that salts of this kind not only present a far more pronounced and longer-lasting anaesthetic effect than benzydamine or the hydrochloride thereof but also enhance the anti-inflammatory effect and, surprisingly reduce the irritating action, thus widening the gap between active and irritant concentrations or doses. Indeed, it is known that, as an anaesthetic or anti-inflammatory agent, benzydamine presents some disadvantages, such as the brevity of its topical action, as the drug quickly passes from the application site into the system, and the onset of an irritant action, which occurs at doses not far removed from those required for the desired effects. It has further been found according to the invention that the activity of the hyaluronic acid salts with anaesthetics can vary depending upon the molecular weight of the hyaluronic acid. For one of the preferred anaesthetics, benzydamine, it was found that the product has the most improved characteristics when salified with a low molecular weight fraction of hyaluronic acid. For another preferred anaesthetic, bupivacaine, it was found that the product has the most improved characteristics when salified with a high molecular weight fraction of hyaluronic acid. It has also been found that of the alkaline and alkaline earth metals, sodium salts are the preferred monovalent salts, and calcium salts are the preferred bivalent salts.
It follows that the new benzydamine salts of the present invention, besides their advantageous application in ophthalmology, like the other anaesthetic bases mentioned previously, have proved to be new drugs with a very wide field of application, for example in inflammatory processes in the mouth or airways such as stomatitis of various origin, tonsillitis or tracheitis, in mucositis caused by radio- or chemotherapy, by surgical or diagnostic intubation, such as bronchoscopy, in dental and gingival disorders in general, including teething trouble in babies, in rhinitis, in inflammatory processes affecting the auditory canal, in conjunctivitis of various origin, in proctological conditions, in traumatic and degenerative-inflammatory processes in the joints, in vulvovaginitis and urethritis of various kinds, including those caused by radio- and chemotherapy, surgical operations, diagnostic manoeuvres, childbirth and, in general, any inflammatory disorder of any kind.
The technical effect of the new hyaluronic acid salts according to the present invention can be demonstrated by the following experimental results relating to its greater anaesthetic action compared to that of the anaesthetic component used on its own (Tables 1-6), in dry inflammation of the eye in rabbit. Benzydamine salts too show a reduction in the substance's irritant action (Tab 7). BIOLOGICAL TESTS
A. ASSESSMENT OF THE ANAESTHETIC EFFECT ON RABBIT CORNEA OF HYALURONIC ACID SALTS WITH LOCAL ANAESTHETICS
METHODS
Corneal Anaesthesia
Corneal anaesthesia was assessed by the method of Camougis and Tankman (Camougis et al. (1971), "Methods in Pharmacology", Vol. 1, A. Schwartz Ed., Appleton-Century-Crofts, New York, p. 1) by measuring the blinking reflex in rabbit. Fifty ml of solution was instilled in the conjunctival sac. The blinking reflex, tested with a bristle, was measured before instillation and then every 5-10 minutes until one hour after treatment. At each test time the degree of anaesthesia was expressed by means of a score of up to 10 given by the number of stimulations before the eye-blink reflex was obtained. The overall anaesthetic effect for each compound was then quantified by the area under curve (AUC) of the degree of anaesthesia over time.
RESULTS As indicated by the results in Table 1, the hyaluronate salts of lidocaine, bupivacaine and benzydamine present greater local activity than their respective hydrochloride salts. As can be observed the effect of increasing the action of the anaesthetics varies according to the alkaline or alkaline/earth ion; the presence of calcium, unlike sodium, selectively favours lidocaine rather than bupivacaine or benzydamine.
Table 1: Anaesthetic effect in rabbit eye by hyaluronate of lidocaine, bupivacaine, benzydamine (FID 60.20XX) and their respective hydrochloride salts.
Compound* Dose§ Anaesthesia (AUC)$
(concentration)
Lidocaine HC1 1% 100
FID 60.2070 1% 167
(100% lidocaine) FID 60.2071 1% 244
(50% lidocaine - 50% Na)
FID 60.2072 1% 222
(50% lidocaine - 50% Ca)
FID 60.2088 1% 200
(50% lidocaine - 50%K)
Bupivacaine HC1 0.125% 100
FID 60.2082 0.125% 166 (100% bupivacaine)
FID 60.2083 0.125% 205
(50% bupivacaine - 50% Na)
FID 60.2084 0.125% 112
(50% bupivacaine - 50% Ca)
Benzydamine Hcl 0.125% 100
FID 60.2096 0.125% 153
(50% benzydamine - 50% Na)
FID 60.2097 0.125% 110 (50% benzydamine - 50% Ca)
* For the hyaluronate salts, the % of active principle and that of alkaline or alkaline earth ion are shown; § the doses refer in all cases to the active principle as a hydrochloride salt; $ AUC measurements of the anaesthetic effect are calculated by taking the reference active principle value as 100. This ion selectivity has proved to also depend upon the molecular weight of the hyaluronic acid used. As can be seen from Table 2, the ion selectivity only exists in low-molecular-weight hyaluronic acid, specifically molecular weight range of 50-350 kDa (derivatives FID 6020XX), and not in high-molecular-weight hyaluronic acid, molecular weight range of 500-730 Kda and 750-1200 (derivatives FID 61.20XX and FID 62.20XX, respectively).
Table 2: Anaesthetic effect in rabbit eye by hyaluronate salts of bupivacaine, according to the molecular weight of the hyaluronic acid of the alkaline or alkaline earth counterion.
Compound* Dose $ Anaesthesia (AUC)$
FID 60.2082 0.125% 100 (100% bupivacaine)
FID 60.2083 0.125% 123
(50% bupivacaine - 50% Na)
FID 60.2084 0.125% 84
(50% bupivacaine - 50% Ca)
FID 61.2082 0.125% 100 (100% bupivacaine)
FID 61.2083 0.125% 96
(50% bupivacaine - 50% Na)
FID 61.2084 0.125% 104
(50% bupivacaine - 50% Ca)
FID 62.2082 0.125% 100
(100% bupivacaine)
FID 62.2083 0.125% 116
(50% bupivacaine - 50% Na) FID 62.2084 0.125% 110
(50% bupivacaine - 50% Ca)
* For the hyaluronate salts, the % of active principle and that of alkaline or alkaline earth ion are shown;
§ the doses refer in all cases to the active principle as a hydrochloride salt; $ AUC measurements of the anaesthetic effect are calculated by taking the reference product value as 100.
Moreover, as can be seen from Table 3, the degree of activity depends on the molecular weight of the hyaluronic acid used.
Table 3: Anaesthetic effect on rabbit eye by hyaluronate salts of bupivacaine according to the molecular weight of the hyaluronic acid.
Compound* Dose § Anaesthesia (AUC)$
Bupivacaine Hcl 0.125% 100
FID 60.2083 0.125% 123
(50% bupivacaine - 50% Ca)
FID 61.2083 0.125% 169 (50% bupivacaine - 50% Na)
FID 62.2083 0.125% 168
(50% bupivacaine - 50% Na)
Bupivacaine Hcl 0.125% 100
FID 60.2084 0.125% 102
(50% bupivacaine - 50% Ca)
FID 61.2084 0.125% 180
(50% bupivacaine - 50% Ca) FID 62.2084 0.125% 205
(50% bupivacaine - 50% Ca)
* For the hyaluronate salts, the % of active principle and that of alkaline or alkaline earth ion are shown;
§ the doses refer in all cases to the active principle as a hydrochloride salt; $ AUC measurements of the anaesthetic effect are calculated by taking the reference product value as 100.
Among monovalent alkaline salts, the most active derivatives are obtained by salification with sodium, as can be seen in Table 4, where derivatives of lidocaine with hyaluronic acid having a molecular weight range between 50 and 350 Kda are reported.
Table 4: Anaesthetic effect on rabbit eye by hyaluronate salts of lidocaine and its alkaline salts.
Compound* Dose § Anaesthesia (AUC)$
Lidocaine Hcl 0.125% 100
FID 60.2087 0.125% 197
(50% lidocaine - 50% Li)
FID 61.2083 0.125% 244 (50% lidocaine - 50% Na)
FID 62.2083 0.125% 173
(50% lidocaine - 50% K)
* For the hyaluronate salts, the % of active principle and that of alkaline ion are shown; § the doses refer in all cases to the active principle as a hydrochloride salt;
$ AUC measurements of the anaesthetic effect are calculated by taking the reference product value as 100.
The degree of salification influences the biological activity of the derivatives, as can be seen in Table 5, where partial salts with bupivacaine and sodium of hyaluronic acid having a molecular weight range between 500 and 730 Kda are reported in comparison to the hydrochloride and the total salt; and in Table 6, where partial salts with benzydamine and sodium of hyaluronic acid having a molecular weight range between 50 and 350 Kda are reported in comparison to the hydrochloride.
Table 5: Anaesthetic effect on rabbit eye by hyaluronate salts of bupivacaine according to the degree of salification.
Compound* Dose § Anaesthesia (AUC)$
Bupivacaine HC1 0.125% 100
FID 61.2110 0.125% 171
(50% bupivacaine - 74% Na)
FID 61.2083 0.125% 169
(50% bupivacaine - 50% Na)
FID 61.2109 0.125% 221
(75% bupivacaine - 25% Na)
FID 61.2082 0.125% 314
(100% bupivacaine)
* For the hyaluronate salts, the % of active principle and that of alkaline ion are shown;
§ the doses refer in all cases to the active principle as a hydrochloride salt; $ AUC measurements of the anaesthetic effect are calculated by taking the reference product value as 100.
Table 6: Anaesthetic effect on rabbit eye by hyaluronate salts of benzydamine according to the degree of salification.
Compound* Dose § Anaesthesia (AUC)$
Benzydamine HC1 0.125% 100
FID 60.2102 0.125% 143
(10% benzydamine - 90% Na)
FID 60.2101 0.125% 148 (25% benzydamine - 75% Na)
FID 60.2096 0.125% 153
(50% benzydamine - 50% Na)
FID 60.2108 0.125% 197
(75% benzydamine - 25% Na)
FID 60.2107 0.125% 181
(90% benzydamine - 10% Na)
* For the hyaluronate salts, the % of active principle and that of alkaline ion are shown; § the doses refer in all cases to the active principle as a hydrochloride salt; $ AUC measurements of the anaesthetic effect are calculated by taking the reference product value as 100.
B. ASSESSMENT OF THE REDUCTION OF THE IRRITANT EFFECT OF BENZYDAMINE SALTS IN RAT PAW
METHODS Irritation
0.1 ml of each of the test solutions (1%, w/v, in hydrochloride salt) was injection into the hind paw of rat. The paw volume was measured with a plethismometer before injection and then 30-60- 120-240-480 minutes after. The oedema and consequent irritant effect were measured on the basis of the increase in the volume of the paw. The irritant effect is expressed by the sum of the increase in volume at the various measuring times.
RESULTS
The hyaluronate salt proved to be less irritating than the hydrochloride salt, as indicated by its lesser oedema-forming effect (Table 7).
Table 7: Irritant effect of benzydamine Hcl and FID 60.2108 in rat paw.
Compound No. Oedema mean cumulative volume
(ml)
Benzydamine Hcl mg 20 529 FID 60.2108 1 mg 20 389 (75% benzydamine 25% Na)
In the case of FXD 60.2108, the % of active principle and that of Na ion are indicated. All doses refer to the active principle as a hydrochloride salt.
METHODS OF PREPARATION The types of hyaluronic acid and basic anaesthetics to be used as starting products are already known and can be prepared by the known processes, as described hereafter. The invention can be illustrated by the following Examples:
Example 1
The hyaluronic acid sodium salt (molecular weight 50 - 350 Kda) is solubilized in water to a concentration of 16 mg/ml. A column is filled with acid resin Bio-Rad AG50W-X8, pretreated with Hcl IN, using a glass column fitted with a jacket inside which there is a flow of fluid at 4°C; 5 ml of resin in acid form are loaded in the column and washed with water to a neutral Ph. At this point the solution of hyaluronic acid sodium salt is passed through the resin, and the resulting solution is collected in a container with a thermostat set at 4°C. The flow in the column is regulated by a peristaltic pump fitted to the outlet of the column. Once all the solution has passed through the column, the resin is washed with water to minimize any loss of product, and the products of these washes are added to the hyaluronic acid solution, thus obtaining a final solution with a concentration of 11.8 mg/ml, expressed as hyaluronic acid.
Example 2
The hyaluronic acid sodium salt (molecular weight 500 - 730 Kda) is solubilized in water to a concentration of 5.0 mg/ml. A column is filled with acid resin Bio-Rad AG50W-X8, pretreated with HCl IN, using a glass column fitted with a jacket, inside which fluid flows at a temperature of 4°C; 5 ml of resin in acid form are loaded in the column and washed with water until a neutral pH is reached. At this point the hyaluronic acid sodium salt solution is passed through the resin, collecting the resulting solution in a container set at temperature of 4°C.
The fluid in the column is regulated by a peristaltic pump fitted onto the outlet of the column. Once the solution has passed through the column, the resin is washed with water to minimize any loss of product, and the product of these washes is added to the hyaluronic acid solution, thus obtaining a final solution with a concentration of 3.78 mg/ml, expressed as hyaluronic acid.
Example 3
Hyaluronic acid sodium salt (molecular weight 750 - 1200 kDa) is solubilized in water to a concentration of 3.0 mg/ml. A column is filled with acid resin. Bio-Rad AG50W-X8 pretreated with HCl IN, using a glass column fitted with a jacket through which fluid flows at a temperature of 4°C; 5 ml of resin in acid form is loaded in the column and washed with water to a neutral pH. At this point, the hyaluronic acid sodium salt is passed through the resin, collecting the resulting solution in a container with a thermostat set at 4°C.
The flow through the column is regulated by a peristaltic pump fitted onto the outlet of the column. Once the solution has passed through the column, the resin is washed with water to minimize any loss of product, then adding the product of the washes to the hyaluronic acid solution, thus obtaining a final solution with a concentration of 2.36 mg/ml, expressed as hyaluronic acid.
Example 4
80 ml of an aqueous solution of hyaluronic acid, prepared as described in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.77 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution. The salification reaction is considered to be complete when there is no more suspended precipitate in the solution.
At this point the solution is filtered on a Gooch 4 filter, subdivided into yellow glass bottles and freeze-dried. The stoichiometrically neutral salt of hyaluronic acid with benzydamine is thus obtained.
The benzydamine to use as starting product can be prepared as of follows: 3.0 g of benzydamine hydrochloride are solubilized in water at a concentration of 50 mg/ml. An equimolar quantity of NaOH IN is added, plus 5% excess, so as to give the aqueous solution a pH of between 10 and 11.
In these conditions the benzydamine base is released and separates from the water as an oil. It is partitioned with ethyl ether (two 50 ml partitionings) to extract the base completely. The ether phases are pooled dehydrated with anhydrous sodium sulfate, then evaporated to dryness and the oily residue is vacuum-dried. The product thus obtained is tested for purity on TLC (eluent: ethyl acetate/methanol 70:30; Rf = 0.14).
Example 5
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.58 g of benzydamine base diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert- butanol which are then added to the hyaluronic acid solution. A few hours later, when there is no more suspended precipitate in the solution, 0.62 ml of NaOH IN is added and shaken for another 30 minutes. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (75%) with benzydamine and partially salified (25%) with sodium.
The benzydamine to be used as starting product can be prepared as described in Example 4.
Example 6 80 ml of an aqueous solution of hyaluronic acid, prepared as described in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop into the hyaluronic acid solution. A white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution. Some hours later, when there is no more suspended precipitate present in the solution, 1.25 ml of NaOH IN are slowly added and the mixture is shaken for another 30 minutes. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (50%) with benzydamine and partially salified (50%) with sodium is thus obtained.
The benzydamine used as starting product can be prepared as described in Example 4.
Example 7 80 ml of an aqueous solution of hyaluronic acid, prepared as described in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution. Some hours later, when there is no longer any suspended precipitate in the hyaluronic acid solution, 92.6 mg of Ca(OH)2 are added and the mixture is shaken for several hours. The salification reaction is considered to be complete when there is no more precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (50%) with benzydamine and partially salified (50%) with calcium, is thus obtained.
The benzydamine used as starting product can be prepared as described in Example 4.
Example 8
250 ml of an aqueous solution of hyaluronic acid, prepared as in Example 2, at a concentration of 3.78 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution. A white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 10 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution. Some hours later, when there is no longer any suspended precipitate in the hyaluronic acid solution, 1.25 ml of NaOH IN are added and the mixture is shaken for another 30 minutes. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (50%) with benzydamine and partially salified (50%) with calcium, is thus obtained.
The benzydamine used as starting product can be prepared as described in Example 4.
Example 9
250 ml of an aqueous solution of hyaluronic acid, prepared as in Example 2, at a concentration of 3.78 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert-butanol which are then added to hyaluronic acid solution. A few hours later, when there is no longer any suspended precipitate in the solution, 92.6 mg of Ca(OH)2 is added and the mixture is shaken for a few hours. The salification reaction is considered to be complete when there is no more precipitate in the solution. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (50%) with benzydamine and partially salified (50%) with calcium is thus obtained.
The benzydamine used as starting product can be prepared as described in Example 4.
Example 10 400 ml of an aqueous solution of hyaluronic acid, prepared as in Example 3, at a concentration of 2.36 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution. A white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 10 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution. Some hours later, when there is no more suspended precipitate in the solution, 1.25 ml of NaOH is added and the mixture is shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (50%) with benzydamine and partially salified (50%) with sodium is thus obtained.
The benzydamine used as starting product can be prepared as described in Example 4. Example 11
400 ml of an aqueous solution of hyaluronic acid, prepared as in Example 3, at a concentration of 2.36 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.39 g of benzydamine base is diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution. A white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert-butanol which are then added to the hyaluronic acid solution. Some hours later, when there is no more suspended precipitate in the solution, 92.6 mg of Ca(OH)2 is added and the mixture is shaken for another few hours. The salification reaction is considered to be complete when there is no longer any precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (50%) with benzydamine and partially salified (50%) with calcium is thus obtained.
The benzydamine used as starting product can be prepared as described in Example 4.
Example 12
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.72 g of bupivacaine base is added in solid form to the solution and shaken for several hours. The salification reaction is considered to be complete when there is no longer any suspended precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The stoichiometrically neutral salt of hyaluronic acid with bupivacaine is thus obtained.
The bupivacaine used as starting product can be prepared as follows: 3.0 g of bupivacaine hydrochloride is solubilized in water at a concentration of 25 mg/ml. An equimolar quantity of NaOH IN is added slowly, plus 5% excess, so as to bring the aqueous solution to a pH of between 10 and 11. In these conditions the bupivacaine base is released and separates from the water as a precipitate. The precipitate is filtered through a Gooch G4 filter, washed several times with water, then vacuum-dried. The product thus obtained is tested for purity by assessing its fusion point (107°-108°) and TLC (eluentethyl acetate/methanol 70:30; Rf = 0.79).
Example 13
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask The solution is shaken in a thermostat bath set at 4°C. 0.54 g of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 0.62 ml of NaOH IN is slowly added and shaken for another 30 minutes. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (75%) with bupivacaine and partially salified (25%) with sodium, is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 14
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.36 g of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 1.25 ml of NaOH IN are slowly added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (50%) with bupivacaine and partially salified (50%) with sodium, is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 15
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.36 q of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 46.3 mg of Ca(OH)2 IN are added and shaken. The salification reaction is considered to be complete when there is no longer any precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (50%) with bupivacaine and partially salified (50%) with calcium, is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 16
250 ml of an aqueous solution of hyaluronic acid, prepared as in Example 2, at a concentration of 3.78 mg/ml is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.72 g of bupivacaine base is added in solid form to the solution and shaken for several hours. The salification reaction is considered to be complete when there is no longer any suspended precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The stoichiometrically neutral salt of hyaluronic acid with bupivacaine is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 17
250 ml of an aqueous solution of hyaluronic acid, prepared as in Example 2, at a concentration of 3.78 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.54 g of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 0.62 ml of NaOH IN are slowly added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch 4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (75%) with bupivacaine and partially salified (25%) with sodium is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 18
250 ml of an aqueous solution of hyaluronic acid, prepared as in Example 2, at a concentration of 3.78 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.36 g of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 1.25 ml of NaOH IN is slowly added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (50%) with bupivacaine and partially salified (50%) with sodium is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 19
250 ml of an aqueous solution of hyaluronic acid, prepared as in Example 2, at a concentration of 3.78 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.36 g of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 46.3 mg of Ca(OH)2 is added and shaken. The salification reaction is considered to be complete when there is no longer any suspended precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (50%) with bupivacaine and partially salified (50%) with calcium is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 20
400 ml of an aqueous solution of hyaluronic acid, prepared as in Example 3, at a concentration of 2.36 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.72 g of bupivacaine base is added in solid form to the solution and shaken for several hours. The salification reaction is considered to be complete when there is no longer any suspended precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The stoichiometrically neutral salt of hyaluronic acid with bupivacaine is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 21
400 ml of an aqueous solution of hyaluronic acid, prepared as in Example 3, at a concentration of 2.36 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set a 4°C. 0.54 g of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 0.62 ml of NaOH IN are slowly added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (75%) with bupivacaine and partially salified (25%) with sodium is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 22
400 ml of an aqueous solution of hyaluronic acid, prepared as in Example 3, at a concentration of 2.36 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.36 g of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 1.25 ml of NaOH IN are slowly added and shaken for another 30 minutes. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (50%) with bupivacaine and partially salified (50%) with sodium is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
Example 23
400 ml of an aqueous solution of hyaluronic acid, prepared as in Example 3, at a concentration of 2.36 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.36 g of bupivacaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 46.3 mg of Ca(OH)2 is slowly added and shaken. The salification reaction is considered to be complete when there is no longer any precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (50%) with bupivacaine and partially salified (50%) with calcium is thus obtained. The bupivacaine used as starting product can be prepared as described in Example 12
Example 24
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1 at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.59 g of lidocaine base is added in solid form to the solution and shaken for several hours. The salification reaction is considered to be complete when there is no longer any suspended precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The stoichiometrically neutral salt of hyaluronic acid with lidocaine is thus obtained. The lidocaine used as starting product can be prepared as follows; 3.0 g of lidocaine hydrochloride is solubilized in water to a concentration of 25 mg/ml. An equimolar quantity of NaOH is slowly added, plus an excess of 5%, so as to give the aqueous solution a pH of between 10 and 11. In these conditions, lidocaine base is released and this separates from the water in the form of a precipitate. The precipitate is filtered through a Gooch G4 filter, washed several times with water and then vacuum-dried. The purity of the product thus obtained is tested by means of its fusion point (68°-69°C) and TLC (eluent: ethyl acetate/methanol 70:30;Rf = 0.81) Example 25
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 40°C. 0.44 g of lidocaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 0.62 ml of NaOH IN are slowly added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (75%) with lidocaine and partially salified (50%) with sodium is thus obtained. The lidocaine used as starting product can be prepared as described in Example 24.
Example 26
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 3, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.29 g of lidocaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 1.25 ml of NaOH IN is slowly added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (50%) with lidocaine and partially salified (50%) with sodium is thus obtained. The lidocaine used as starting product can be prepared as described in Example 24.
Example 27
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 500 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.44 g of lidocaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 23 mg of Ca(OH)2 is added and shaken. The salification reaction is considered to be complete when there is no longer any precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (75%) with lidocaine and partially salified (25%) salified with calcium is thus obtained.
The lidocaine used as starting product can be prepared as described in Example 24. Example 28
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.29 g of lidocaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 46.3 mg of Ca(OH)2 is slowly added and shaken. The salification reaction is considered to be complete when there is no longer any precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (50%) with lidocaine and partially salified (50%) with calcium is thus obtained
The lidocaine used as starting product can be prepared as described in Example 24.
Example 29
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.29 g of lidocaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 36.5 mg of Mg(OH)2 is added and shaken. The salification reaction is considered to be complete when there is no longer any precipitate in the solution.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (50%) with lidocaine and partially salified (50%) with magnesium is thus obtained,
The lidocaine used as starting product can be prepared as described in Example 24.
Example 30
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.29 g of lidocaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 1.25 ml of LiOH IN is slowly added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partially salified (50%) with lidocaine and partially salified (50%) with lithium is thus obtained.
The lidocaine used as staring product can be prepared as described in Example 24. Example 31
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml, is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.29 g of lidocaine base is added in solid form to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 1.25 ml of KOH IN is added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt partial salified (50%) with lidocaine and partially salified (50%) with potassium is thus obtained. The lidocaine used as starting product can be prepared as described in Example 24.
Example 32
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.69 G of benzydamine base are diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert- butanol which are then added to the hyaluronic acid solution. A few hours later, when there is no more suspended precipitate in the solution, 0.25 ml of NaOH IN is added and shaken for another 30 minutes. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (90%) with benzydamine and partially salified (10%) with sodium is thus obtained.
The benzydamine to be used as starting product can be prepared as described in Example 4.
Example 33 80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.19 g of benzydamine base are diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert- butanol which are then added to the hyaluronic acid solution. A few hours later, when there is no more suspended precipitate in the solution, 1.87 ml of NaOH IN is added and shaken for another 30 minutes. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (25%) with benzydamine and partially salified (75%) with sodium is thus obtained.
The benzydamine to be used as starting product can be prepared as described in Example 4.
Example 34
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.08 g of benzydamine base are diluted with 10 ml of tert-butanol and the solution is slowly added drop by drop to the hyaluronic acid solution: a white precipitate is formed which disappears within a few hours. The container used to weigh the benzydamine is washed with two 5 ml aliquots of tert- butanol which are then added to the hyaluronic acid solution. A few hours later, when there is no more suspended precipitate in the solution, 2.24 ml of NaOH IN is added and shaken for another 30 minutes.
At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (10%) with benzydamine and partially salified (90%) with sodium is thus obtained.
The benzydamine to be used as starting product can be prepared as described in Example 4.
Example 35
80 ml of an aqueous solution of hyaluronic acid, prepared as in Example 1, at a concentration of 11.8 mg/ml is placed in a 100 ml flask. The solution is shaken in a thermostat bath set at 4°C. 0.18 g of bupivacaine base in solid form is added to the solution and shaken. Several hours later, when there is no longer any suspended precipitate in the solution, 1.87 ml of NaOH IN is slowly added and shaken for another 30 minutes. At this point the solution is filtered through a Gooch G4 filter, subdivided into yellow glass bottles and freeze-dried. The neutral salt, partially salified (25%) with bupivacaine and partially salified (75%) with sodium, is thus obtained.
The bupivacaine used as starting product can be prepared as described in Example 12.
PHARMACEUTICAL PREPARATIONS
Preparation 1:
Preparation of a mouthwash containing Benzydamine hyaluronate (75%)
100 ml of solution contain:
- Benzydamine hyaluronate 357 mg
(equal to 134.4 mg of benzydamine base) Excipients
- Glycerol 5000 mg
- ethyl alcohol 95° 7926 mg
- Saccharine 30 mg
- Methyl p-hydroxybenzoate 180 mg
- Propyl p-hydroxybenzoate 20 mg
- Peppermint flavouring 42.62 mg
- Quinoline yellow colouring (E104) 0.87 mg
- Blue patent V colouring (E131) 0.14 mg
- Purified water q.s. to 100 ml
Preparation 2:
Preparation of a spray containing Benzydamine hyaluronate (75%)
100 ml of solution contain:
- Benzydamine hyaluronate 357 mg (equal to 134.4 mg of benzydamine base) Excipients
- Glycerol 5000 mg
- Ethyl alcohol 95° 7926 mg
- Saccharine 30 mg - Methyl p-hydroxybenzoate 180 mg
- Propyl p-hydroxybenzoate 20 mg
- Peppermint flavouring 42.62 mg
- Purified water q.s. to 100 ml
Preparation 3: Preparation of a proctological cream containing Benzydamine hyaluronate (75%) 100 ml of cream contain: - Benzydamine hyaluronate 1190 mg (equal to 448 mg of benzydamine base) Excipients
- Vaseline 8000 mg
- Vaseline oil 4000 mg - Lanolin 12000 mg
- Polysorbate 80 5000 mg
- Propylene glycol 6000 mg
- Methyl p-hydroxybenzoate 93.5 mg
- Propyl p-hydroxybenzoate 34 mg - Lavender essence 42 mg
- Purified water q.s. to 100 ml
Preparation 4:
Preparation of a gynaecological solution containing Benzydamine hyaluronate (75%) 100 ml of solution contain:
- Benzydamine hyaluronate 238 mg Excipients:
- Trimethylacetylammonium-p-toluene sulfonate 100 mg
- Red rose scent 0.1 ml - Purified water q.s. to 100 ml
The invention being thus described, it is clear that these methods can be modified in various ways. Said modifications are not to be considered as divergences from the spirit and purposes of the invention, and any modification which would be apparent to an expert in the field comes within the scope of the following claims.

Claims

CLAIMS:
1. A medicament for topical administration comprising a stoichiometrically neutral salt of hyaluronic acid with a basic anaesthetic containing aliphatic and/or aromatic amino groups, in which at least 50% of the carboxy groups of the hyaluronic acid are salified with the basic anaesthetic and the remaining carboxy groups are salified with an alkaline or alkaline earth metal.
2. A medicament for topical administration according to claim 1, wherein the alkaline metal is sodium.
3. A medicament for topical administration according to claim 1, wherein the alkaline earth metal is calcium.
4. A medicament for topical administration according to any one of claims 1-3, wherein the basic anaesthetic is benzidamine.
5. A medicament for topical administration according to any one of claims 1-3, wherein the basic anaesthetic is bupivacaine.
6. A medicament for topical administration according to any one of claims 1-5, wherein the hyaluronic acid has a molecular weight in the range of 50-1,230 kDa and essentially free of hyaluronic acid with a molecular weight of less than 30 kDa.
7. A medicament for topical administration according to claim 6, wherein the hyaluronic acid has a molecular weight in the range of 50-350 kDa or 500-730 kDa or 750-1,200 kDa.
8. A medicament for topical administration according to any one of claims 1-7, wherein the carboxy groups of hyaluronic are salified with the basic anaesthetics in the range between 70 and 100%.
9. A medicament for topical administration according to claim 8, wherein the carboxy groups of hyaluronic acid are salified with benzidamine in a percentage of about 75%.
10. A medicament for topical administration according to claim 8, wherein the carboxy group of hyaluronic acid are salified with bupivacaine at about 100.
11. A medicament for topical administration according to claim 9, wherein the hyaluronic acid has a molecular weight range between 50-350 kDa.
12. A medicament for topical administration according to claim 10, wherein the hyaluronic acid has a molecular weight in the range of 500-730 kDa.
13. A medicament for topical administration according to claim 10, wherein the hyaluronic acid has a molecular weight in the range of 750-1,200 kDa.
14. Use of a medicament according to any one of claims 1-13 in ophthalmology.
15. Use of a medicament according to any one of claims 1-13 for the treatment of inflammatory processes in the mouth or primary airways, including rhinitis, mucositis caused by radiotherapy or chemotherapy, by intubation during surgery or for diagnostic purposes, in periodontal or gingival conditions, in inflammatory processes in the auditory canal, in conjunctivitis of various origin, in vulvovaginitis, urethritis, or for proctological applications.
16. Use of a medicament according to claim 9, wherein a salt of hyaluronic acid with benzydamine is used as the anaesthetic.
17. Use of a medicament according to claims 14-15 in form of collirium, mouth wash, spray, cream or vaginal solution.
PCT/IB1997/001288 1996-10-17 1997-10-17 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics WO1998017285A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US09/284,668 US6224857B1 (en) 1996-10-17 1997-10-17 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
CA002268967A CA2268967C (en) 1996-10-17 1997-10-17 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
PL97332873A PL190385B1 (en) 1996-10-17 1997-10-17 Pharmaceutic preparations containing a salt of hialuronic acid along with local anaesthetics
DE69732049T DE69732049T2 (en) 1996-10-17 1997-10-17 PHARMACEUTICAL PREPARATIONS, CONTAINING SALTS OF HYALURONIC ACID AND LOCAL ANESTHETICS
AT97943093T ATE285241T1 (en) 1996-10-17 1997-10-17 PHARMACEUTICAL PREPARATIONS CONTAINING SALTS OF HYALURONIC ACID AND LOCAL ANESTHETICS
JP51916298A JP4334620B2 (en) 1996-10-17 1997-10-17 A pharmaceutical product comprising a salt of hyaluronic acid with a local anesthetic
BR9713486-4A BR9713486A (en) 1996-10-17 1997-10-17 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anesthetics.
AU44700/97A AU712927B2 (en) 1996-10-17 1997-10-17 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
EP97943093A EP0956026B1 (en) 1996-10-17 1997-10-17 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
HK00102836A HK1023518A1 (en) 1996-10-17 2000-05-12 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITPD96A000254 1996-10-17
IT96PD000254A IT1287967B1 (en) 1996-10-17 1996-10-17 PHARMACEUTICAL PREPARATIONS FOR LOCAL ANESTHETIC USE

Publications (1)

Publication Number Publication Date
WO1998017285A1 true WO1998017285A1 (en) 1998-04-30

Family

ID=11391550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/001288 WO1998017285A1 (en) 1996-10-17 1997-10-17 Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics

Country Status (14)

Country Link
US (1) US6224857B1 (en)
EP (1) EP0956026B1 (en)
JP (1) JP4334620B2 (en)
KR (1) KR20000049281A (en)
AT (1) ATE285241T1 (en)
AU (1) AU712927B2 (en)
BR (1) BR9713486A (en)
CA (1) CA2268967C (en)
DE (1) DE69732049T2 (en)
ES (1) ES2235254T3 (en)
HK (1) HK1023518A1 (en)
IT (1) IT1287967B1 (en)
TR (1) TR199900860T2 (en)
WO (1) WO1998017285A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106187864A (en) * 2016-07-11 2016-12-07 江苏天和制药有限公司 A kind of method being prepared high-purity bupivacaine alkali by bupivacaine hydrochloride
EP3508197A1 (en) 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
IT201800001890A1 (en) * 2018-01-25 2019-07-25 Fidia Farm Spa PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POSTOPERATIVE PAIN
EP2985027B1 (en) 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Nasal composition comprising mixture of hyaluronic acids and saline solution
EP2985019B1 (en) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338433B2 (en) 2002-08-13 2008-03-04 Allergan, Inc. Remotely adjustable gastric banding method
MXPA05002361A (en) 2002-08-28 2005-09-30 Inamed Medical Products Corp Fatigue-resistant gastric banding device.
DE10246340A1 (en) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Combination preparation of hyaluronic acid and at least one local anesthetic and its use
US7238677B2 (en) * 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
JP4672302B2 (en) * 2003-08-05 2011-04-20 天藤製薬株式会社 Stable local anesthetic composition
US20050095219A1 (en) * 2003-10-29 2005-05-05 Shu-Ping Yang Compositions for promoting vaginal cell proliferation and maturation
NZ548535A (en) 2004-01-23 2010-01-29 Allergan Sales Llc Realeasably-securable one-piece adjustable gastric band
DK1725193T3 (en) 2004-03-08 2009-11-30 Allergan Medical S A Closing system for tubular members
CA2569043C (en) 2004-03-18 2010-08-17 Allergan, Inc. Apparatus and method for volume adjustment of intragastric balloons
US8251888B2 (en) 2005-04-13 2012-08-28 Mitchell Steven Roslin Artificial gastric valve
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US8043206B2 (en) 2006-01-04 2011-10-25 Allergan, Inc. Self-regulating gastric band with pressure data processing
US7798954B2 (en) 2006-01-04 2010-09-21 Allergan, Inc. Hydraulic gastric band with collapsible reservoir
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7993675B2 (en) * 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
JP2010528046A (en) * 2007-05-23 2010-08-19 アラーガン、インコーポレイテッド Cross-linked collagen and use thereof
US8318695B2 (en) * 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8697044B2 (en) * 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
KR101577471B1 (en) 2007-11-16 2015-12-14 알러간, 인코포레이티드 Compositions and methods for treating purpura
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
AU2009257390B2 (en) 2008-06-12 2014-09-04 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
EP2324064B1 (en) 2008-09-02 2017-11-08 Tautona Group LP Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
EP2362762A1 (en) 2008-10-06 2011-09-07 Allergan Medical Sàrl Mechanical gastric band with cushions
WO2010042427A2 (en) * 2008-10-06 2010-04-15 Microbial Defense Systems, Llc Antimicrobial composition and methods of making and using same
US20100305397A1 (en) * 2008-10-06 2010-12-02 Allergan Medical Sarl Hydraulic-mechanical gastric band
US20100185049A1 (en) 2008-10-22 2010-07-22 Allergan, Inc. Dome and screw valves for remotely adjustable gastric banding systems
US8390326B2 (en) * 2009-05-05 2013-03-05 William Marsh Rice University Method for fabrication of a semiconductor element and structure thereof
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US8758221B2 (en) 2010-02-24 2014-06-24 Apollo Endosurgery, Inc. Source reservoir with potential energy for remotely adjustable gastric banding system
US8840541B2 (en) * 2010-02-25 2014-09-23 Apollo Endosurgery, Inc. Pressure sensing gastric banding system
JP5749283B2 (en) 2010-03-12 2015-07-15 アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｉｎｄｕｓｔｒｉｅ Ｓａｓ Fluid composition for improving skin condition
US8691279B2 (en) 2010-03-22 2014-04-08 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9028394B2 (en) 2010-04-29 2015-05-12 Apollo Endosurgery, Inc. Self-adjusting mechanical gastric band
US20110270024A1 (en) 2010-04-29 2011-11-03 Allergan, Inc. Self-adjusting gastric band having various compliant components
US9044298B2 (en) 2010-04-29 2015-06-02 Apollo Endosurgery, Inc. Self-adjusting gastric band
US20110270025A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Remotely powered remotely adjustable gastric band system
US8517915B2 (en) 2010-06-10 2013-08-27 Allergan, Inc. Remotely adjustable gastric banding system
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US20120059216A1 (en) 2010-09-07 2012-03-08 Allergan, Inc. Remotely adjustable gastric banding system
US8961393B2 (en) 2010-11-15 2015-02-24 Apollo Endosurgery, Inc. Gastric band devices and drive systems
EP3456200B1 (en) 2011-05-10 2023-05-03 Next Science IP Holdings Pty Ltd Article having an antimicrobial solid and use thereof
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
EP3536307B1 (en) 2011-06-03 2021-10-20 ALLERGAN Industrie, SAS Dermal filler compositions including antioxidants
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
EP2581079B1 (en) 2011-10-11 2016-12-07 BioPolymer GmbH & Co. KG Combination of hyaluronic acid and prilocaine
US8876694B2 (en) 2011-12-07 2014-11-04 Apollo Endosurgery, Inc. Tube connector with a guiding tip
US8961394B2 (en) 2011-12-20 2015-02-24 Apollo Endosurgery, Inc. Self-sealing fluid joint for use with a gastric band
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
EP3977881A1 (en) 2020-09-04 2022-04-06 Bert Raf Celis Sports clothing for cycling and accompanying cooling methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138572A2 (en) * 1983-10-11 1985-04-24 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
EP0197718A2 (en) * 1985-04-05 1986-10-15 FIDIA S.p.A. New medicaments for topical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1247175B (en) 1991-04-19 1994-12-12 Fidia Spa PROCEDURE FOR PURIFICATION OF HYALURONIC ACID AND FRACTION OF PURE HYALURONIC ACID FOR OPHTHALMIC USE.
ATE267587T1 (en) * 1995-06-09 2004-06-15 Euro Celtique Sa FORMULATIONS AND METHODS FOR PROLONGED LOCAL ANESTHESIA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138572A2 (en) * 1983-10-11 1985-04-24 FIDIA S.p.A. Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same
EP0197718A2 (en) * 1985-04-05 1986-10-15 FIDIA S.p.A. New medicaments for topical use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DOHERTY ET AL.: "Prolongation of Lidocaine-induced epidural anesthesia by medium molecular weight Hyaluronic acid formulations : pharmacodynamic and pharmacokinetic studies in the rabbit", ANESTH. ANALG., vol. 80, no. 4, April 1995 (1995-04-01), pages 740 - 746, XP000647886 *
HASSAN ET AL.: "Effects of adjuvants to local anaesthesics on their duration : II. Studies of some substituted dextrans and other macromolecules in rat infraorbital nerve block", ACTA ANAESTH. SCAND., vol. 29, no. 4, 1985, pages 380 - 383, XP000647953 *
HASSAN ET AL.: "Effects of adjuvants to local anaesthesics on their duration : III. Experimental studies of Hyaluronic acid", ACTA ANAESTH. SCAND., vol. 29, no. 4, 1985, pages 384 - 388, XP000647952 *
JOHANSSON: "Effects of adjuvants to local anaesthesics on their duration : IV. Effect of hyaluronic acid added to bupivacaine or prilocaine on the duration of nerve blockade in man", ACTA ANAESTH. SCAND., vol. 29, no. 7, October 1985 (1985-10-01), pages 736 - 738, XP000647890 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3508197A1 (en) 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
EP2985027B1 (en) 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Nasal composition comprising mixture of hyaluronic acids and saline solution
EP2985019B1 (en) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
CN106187864A (en) * 2016-07-11 2016-12-07 江苏天和制药有限公司 A kind of method being prepared high-purity bupivacaine alkali by bupivacaine hydrochloride
CN106187864B (en) * 2016-07-11 2018-11-23 江苏天和制药有限公司 A method of high-purity Bupivacaine alkali is prepared by bupivacaine HCl
IT201800001890A1 (en) * 2018-01-25 2019-07-25 Fidia Farm Spa PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POSTOPERATIVE PAIN

Also Published As

Publication number Publication date
ITPD960254A1 (en) 1998-04-17
AU4470097A (en) 1998-05-15
JP4334620B2 (en) 2009-09-30
DE69732049D1 (en) 2005-01-27
JP2001503042A (en) 2001-03-06
ATE285241T1 (en) 2005-01-15
CA2268967C (en) 2003-02-04
AU712927B2 (en) 1999-11-18
DE69732049T2 (en) 2006-03-02
US6224857B1 (en) 2001-05-01
EP0956026A1 (en) 1999-11-17
EP0956026B1 (en) 2004-12-22
TR199900860T2 (en) 1999-06-21
KR20000049281A (en) 2000-07-25
CA2268967A1 (en) 1998-04-30
BR9713486A (en) 2000-04-11
IT1287967B1 (en) 1998-09-10
HK1023518A1 (en) 2000-09-15
ES2235254T3 (en) 2005-07-01

Similar Documents

Publication Publication Date Title
US6224857B1 (en) Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
US5972326A (en) Controlled release of pharmaceuticals in the anterior chamber of the eye
EP0197718B1 (en) New medicaments for topical use
CA2251982C (en) Ophthalmic compound with extended dwell time on the eye
SG176525A1 (en) Gel useful for the delivery of ophthalmic drugs
CA2055434A1 (en) Paracetamol-based pharmaceutical composition
WO2013043387A1 (en) Ophthalmic gel compositions
CZ431399A3 (en) Process for preparing pharmaceutical preparation
IE52986B1 (en) Eye-lorion composition containing chondroitin sulphate a
AU2014216273A1 (en) Topical ocular analgesic agents
RU2481835C2 (en) Wound-healing medication for local application
MXPA99003616A (en) Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
JP2530176B2 (en) Ophthalmic composition
KR20090081083A (en) Eye composition comprising alginic acid based compounds and method of preparing the same
JPH11279205A (en) Suppression of decomposition of hyaluronic acid preparations
PT93897A (en) METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION OF SODIUM CHROMOGLYLATE AND CARBOXY-POLYMETHYLENE
EP3900714A1 (en) Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
CN107249554B (en) Hyaluronic acid decomposition inhibitor containing sodium 2-mercaptoethanesulfonate and composition containing the same
PT1927353E (en) Remedy for corneal diseases
KR102540969B1 (en) Composition for promoting skin-regeneration containing sodium 2-mercaptoethane sulfonate
PL190385B1 (en) Pharmaceutic preparations containing a salt of hialuronic acid along with local anaesthetics
KR20210158494A (en) Alcohol-based Disinfectants Having Moisturizing effect and Manufacturing Method Thereof
WO2016159684A1 (en) Composition for promoting skin regeneration containing sodium 2-mercaptoethane sulfonate
JPH0338526A (en) Eye-water composition
KR20180095555A (en) Aminophosphinic acid derivatives for the prevention and treatment of eye pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE ES FI FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2268967

Country of ref document: CA

Ref document number: 2268967

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997943093

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019997003392

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 519162

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/003616

Country of ref document: MX

Ref document number: 1999/00860

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 09284668

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997943093

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997003392

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019997003392

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997943093

Country of ref document: EP